The antibody Rituximab that was originally used to treat non-Hodgkin's lymphoma or chronic lymphocytic leukemia was found to be effective for all autoimmune diseases studied so far. This raises the question of whether successful treatment of autoimmune reactions, even at the subclinical level, can reduce the risk of cardiovascular disease, cancer, and other age-associated diseases. Animal experiments and initial clinical observations support this novel therapeutic strategy. However, due to the complex biological processes and the long-time required for clinical observations, it is challenging to produce clear evidence from randomized double-blinded studies. It will be crucial to prove in the near future, whether surrogate endpoints (e.g., elimination of autoreactive B cells) can accelerate the development of this strategy. The present preclinical evidence is convincing, but the path from a "promising anti-aging molecule" to "accepted drug" will be long and require further research.
Therapeutic approaches to ageing and AAD with anti-CD-20 Antibodies
Ageing is associated with an age-related increased number of mutations in all cell lineages capable of proliferation, which appear to play a significant role in age-related inflammation in virtually all organs. The process of cellular senescence is also associated with inflammation (Gewirtz 2014; Hodes, Sierra et al. 2016 ) most likely also promoting immune reactions including autoimmunity. However, the likely relationship between senescence, mutations, and autoimmunity has yet to be investigated. While numerous strategies to delay or prevent ageing have been explored in experimental and clinical studies (Rattan 2005) , none of these have to our knowledge as yet studied or proposed targeting antibodies and autoimmunity in order to ameliorate or slow down the syndrome of ageing and age-associate disorders (AAD). AAD are, in our opinion, not isolated disorders but part of a syndrome of interrelated disorders and interrelated pathogenetic pathways with the acquisition of genetic and epigenetic alterations with age as a major contributing factor. We have proposed the term "Omega-Syndrome" for this syndrome of age-associated disorders (Faletti 2019) .
Immunosupportive therapies of aging have been proposed (Fulop, Larbi et al. 2007 ). However, if our hypothesis is correct, that antibodies and autoantibodies play a major role in the pathogenesis of this syndrome, clinical evaluation of anti-CD-20 antibodies, which have shown clinical activity in probably all autoimmune disorders they have been tested in, is warranted (Franks, Getahun et al. 2016 ).
Long-term clinical observations for more than 15 years of a large number of patients after receiving Rituximab suggest, that these patients rarely develop or suffer from cardiovascular events, show an impressive performance status, and, if they develop secondary or tertiary cancers do remarkably well (Mertelsmann et al. unpublished) . In fact, this review article has been prompted by these clinical observations. In addition to doing remarkably well, unexpected benefits of anti-CD20 therapy have been observed in several patients. Two case vignettes may serve as an example. 
Anti-CD 20 Monoclonal Antibodies
Rituximab is a chimeric monoclonal antibody (IgG1) which was developed in the 1990s for the treatment of non-Hodgkin's lymphoma of B-cell origin (Pescovitz 2006) . It was first licensed 1997 for the treatment of follicular lymphoma, later for diffuse large non-Hodgkin's lymphoma and chronic lymphatic leukemia. Subsequently, it was shown to be active against all CD 20 positive malignant lymphomas. In 2006 Rituximab was licensed for the treatment of the autoimmune disease Rheumatoid arthritis (RA).
In 2013 it was licensed for the treatment of ANCA associated vasculitis. It is also widely used off-label for the treatment of other autoimmune diseases, even those that were hitherto considered to be T cell disorders such as multiple sclerosis.
Recently, generic and novel fully humanized anti-CD20 antibodies have become available, e.g.
Obinutuzumab and Ofatumumab. While there is no cross-resistance in some patients, in general, activity and side-effects appear to be very similar. Recently, Li et al. (Li, Zhang et al. 2015 ) described a novel multi-component anti-CD20 mAb nanocluster, which demonstrated activity in a Rituximab-resistant B-cell lymphoma, demonstrating that future development of current anti-CD20 strategies might further enhance the efficacy of anti-CD20 strategies.
Current Clinical Indications for Rituximab/ Ofatumumab/ Ocrelizumab
Since Rituximab`s approval for the treatment of B-cell lymphomas in 1997, it has significantly improved the clinical course and prognosis of these patients (Pavanello, Zucca et al. 2017; Salles, Barrett et al. 2017 ). Subsequently, it has been approved for certain autoimmune disorders and furthermore been employed off-label in a very broad spectrum of autoimmune disorders (Edwards and Cambridge 2006) .
In certain hematological autoimmune disorders such as immune thrombocytopenia (ITP) and autoimmune hemolytic anemia, Rituximab is highly effective, probably associated with fewer side-effects than with other treatments (Barcellini and Zanella 2011) . Unfortunately, there is no approval by the regulatory agencies for many rare indications, since no clinical trials in these rare disorders have been performed and are apparently of no interest to the respective pharmaceutical companies. Since insurance companies in many instances will only pay for Rituximab in approved indications, many patients currently receive more toxic regimens for their disorder, a highly regrettable state of affairs. It is striking that B cell depletion is also of therapeutic benefit in autoimmune disorders in which a T cell-mediated pathogenesis has been implicated until now. While T cells might still be at the root of pathogenesis, apparently B cell mediated effects dominate the clinical effects, which are responsive to Rituximab. lymphomas. B-cell lymphomas frequently carry an idiotype which recognizes low affinity autoantigens (Sachen, Strohman et al. 2012) . Thus, they can be considered as the malignant progression of a preexisting autoreactive B cell clone. Similarly, 33 % of idiotypes in Myeloma have been shown to recognize lysolipids (Nair, Branagan et al. 2016) .
B-cell depletion and
Unexpected clinical benefits of Rituximab beyond the treatment of malignant lymphoma and autoimmune disorders observed in patients after Rituximab therapy during long-term clinical follow-up include the following observations and related questions:
• Case Vignettes: Virus-associated Merkel Cell Cancer goes into lasting remission, viral Plantar Warts disappear,
• Clinical Performance Status increases.
• Reduction in the incidence of other AAD, e.g. CVS?
• Survival advantage in clinical trials +/-Rituximab in NHL, only due to NHL effect?
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We propose that autoimmunity should be evaluated as a therapeutic target for the prevention and treatment of AAD and that anti-CD20 antibodies could be excellent drugs to evaluate, since Rituximab removes unnecessary, potentially harmful B cells, as well as B cells with genetic alterations like in malignant lymphoma.
As discussed above, in some patients no significant decrease of immunoglobulins and B-cells after Rituximab is observed, which appears to be due to patient-specific factors, possibly Long-term clinical observations and regular follow-up will be required to further understand the association of AAD and autoimmunity. Prospective clinical trials lasting for decades appear highly unlikely, because of the logistic challenges involved in such a study and since each patient has and will develop unique constellations of diseases and cofactors during such a long-term follow-up. Case series or cohorts of consecutively treated patients and controls might help to unravel the complexity of the Omega Syndrome of ageing and AAD. The overwhelming evidence of autoimmunity playing a major role in AAD strongly supports this strategy.
